Intravenous streptokinase in the management of a subset of patients with unstable angina: a randomized controlled trial

Rk, Saran; Bhandari, K.; Narain, V.S.; Ahuja, Rinkey; Puri, Vijay K.; Thakur, R.; Dwivedi, Satyam; Hasan, Mohammad Rashedul

doi:10.1016/0167-5273(90)90062-a

Cited by 14 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50,[53][54][55] It is important to adjust for age in sex comparisons because the on- Table 1. Eight Important Guideline Recommendations (1) No intravenous thrombolytics [18][19][20][23][24][25][26][27][28] Potential candidates: All patients. Exclusions: Left bundle-branch block.…”

Section: Commentmentioning

confidence: 99%

Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina

Giugliano¹,

Camargo²,

Lloyd‐Jones³

et al. 1998

Arch Intern Med

116

View full text Add to dashboard Cite

Older patients were less likely to receive standard therapies for unstable angina before release of the 1994 AHCPR guideline. Patients presenting with congestive heart failure also received care that was more discordant with guideline recommendations. The AHCPR guideline allows identification of patients who receive nonstandard care and, if applied to those patients with the greatest likelihood to benefit, could lead to improved health care delivery.

show abstract

Section: Commentmentioning

confidence: 99%

Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina

Giugliano¹,

Camargo²,

Lloyd‐Jones³

et al. 1998

Arch Intern Med

116

View full text Add to dashboard Cite

show abstract

Thrombolytic therapy for unstable angina

Borzak¹,

Verter²,

Bajwa³

et al. 1993

Clinical Cardiology

View full text Add to dashboard Cite

Summary:Thrombolytic therapy for unstable angina has not gained acceptance as a primary treatment for unstable angina (UA) despite the evidence showing a reduction in mortality when these agents are given for myocardial infarction. The purpose of this review is to examine the clinical value of thrombolytic therapy for UA. The multiple lines of evidence supporting intracoronary thrombus formation as a key mechanism in the pathogenesis of UA are reviewed. Studies examining the effect of thrombolytic therapy on angiopphic endpoints have shown little effect on the extent of luminal narrowing, but do reveal a decrease in angiographically detected thrombus. Thelve randomized, controlled trials of thrombolytic agents in 6 1 1 UA patients with predefined clinical endpoints have been published.These trials varied widely in design and adjunctive thmpy both in treated and control p u p s . Review of thew trials shows a tendency to fewer clinical events such as death, i n f h o n , and need for revascularization in treated patients, with a corresponding increase in bleeding complications. Clinical efficacy of thrombolytic therapy cannot be excluded by the available data, perhaps in part because of insufficient numbers of patients treated. Determination of the net clinical value of thrombolytic therapy must await larger and more definitive trials.

show abstract

Challenge of Thrombolytic Therapy in Unstable Angina Pectoris

Venditto¹,

Ambrose²

1994

Developments in Cardiovascular Medicine

View full text Add to dashboard Cite

Intravenous streptokinase in the management of a subset of patients with unstable angina: a randomized controlled trial

Cited by 14 publications

References 16 publications

Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina

Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina

Thrombolytic therapy for unstable angina

Challenge of Thrombolytic Therapy in Unstable Angina Pectoris

Contact Info

Product

Resources

About